Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) have earned an average rating of “Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $160.9333.
A has been the subject of a number of analyst reports. Royal Bank Of Canada initiated coverage on Agilent Technologies in a research note on Wednesday. They set an “outperform” rating and a $153.00 price objective for the company. Robert W. Baird lifted their price objective on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group decreased their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Wall Street Zen cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, TD Cowen lifted their price objective on Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday.
View Our Latest Stock Report on A
Agilent Technologies Stock Up 17.2%
Agilent Technologies (NYSE:A – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. Agilent Technologies had a return on equity of 24.74% and a net margin of 19.55%.The business had revenue of $1.84 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the firm earned $1.31 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Research analysts predict that Agilent Technologies will post 5.95 EPS for the current year.
Agilent Technologies Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.255 per share. The ex-dividend date is Tuesday, June 30th. This represents a $1.02 annualized dividend and a yield of 0.8%. Agilent Technologies’s payout ratio is currently 22.52%.
Key Stories Impacting Agilent Technologies
Here are the key news stories impacting Agilent Technologies this week:
- Positive Sentiment: Agilent posted second-quarter EPS of $1.49, topping estimates, while revenue rose 10% year over year to $1.83 billion, also ahead of forecasts. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
- Positive Sentiment: The company raised its FY 2026 profit outlook, signaling management confidence in continued demand for medical tools, lab research equipment, and diagnostic products. Agilent raises 2026 profit forecast on strong demand for lab tools
- Positive Sentiment: Bank of America upgraded Agilent to Buy, citing strong execution, improving demand trends, and market share gains in key instrument categories. Agilent Technologies shares jump on earnings beat, Bank of America upgrade
- Positive Sentiment: TD Cowen and Barclays also raised price targets, adding to the positive analyst sentiment around the stock after the earnings release. Agilent Technologies Stock Soars On Broad Q2 Beat, Company Stands Out In Tools Sector
- Neutral Sentiment: Some commentary noted that recurring revenue reached 66% of sales, but that the stock had been under pressure earlier despite the earnings beat and higher guidance.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Flynn Zito Capital Management LLC lifted its position in Agilent Technologies by 3.2% during the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company’s stock worth $290,000 after acquiring an additional 69 shares during the period. Gabelli Funds LLC lifted its position in Agilent Technologies by 1.1% during the 3rd quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company’s stock worth $850,000 after acquiring an additional 74 shares during the period. Fiduciary Trust Co grew its position in Agilent Technologies by 1.6% during the 3rd quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after purchasing an additional 77 shares during the period. NorthCrest Asset Manangement LLC grew its position in Agilent Technologies by 1.6% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,082 shares of the medical research company’s stock worth $726,000 after purchasing an additional 79 shares during the period. Finally, Freestone Capital Holdings LLC grew its position in Agilent Technologies by 2.0% during the 4th quarter. Freestone Capital Holdings LLC now owns 4,218 shares of the medical research company’s stock worth $574,000 after purchasing an additional 84 shares during the period.
About Agilent Technologies
Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.
Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.
See Also
- Five stocks we like better than Agilent Technologies
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
